# MannKind share price today (MannKind Corporation, MNKD)

> MannKind Corporation's balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. MNKD · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/mnkd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.76 (−33.2% in a year)
- P/E: 217.2× (higher than 75% of the last 1 year)
- Revenue (Jun 2026): $109 M (+42.9% on a year ago)
- Profit (Jun 2026): −$19.0 M (−2,949.1% on a year ago)
- Operating margin: −0.8% (−14.7 points on a year ago)
- ROE: −12%, FY25
- ROIC: −2.3%, against a 10.0% cost of capital: −12.3 points
- Profit that came in as cash: 182%, last 2 years

The main question: the share price moved −33.2% in a year while yearly earnings per share moved −80.0%. The difference came from the market paying a higher multiple. ## What is the MannKind share price today? MannKind Corporation's share price was $3.76 at the close on 5 November 2026. That is 1.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $6, and at that close it sat 40% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 9 weeks running. Over the last 1 year the share price moved +0% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does MannKind pay? MannKind Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is MannKind on? MannKind is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is MannKind profitable? MannKind Corporation posted a net loss of $19.0 M in the Jun 2026 quarter. Full-year FY25 profit was $5.9 M. That loss is 17.4% of the quarter's revenue. The same quarter a year earlier earned $668 K. 4 of the last 12 reported quarters were loss-making. Jun 2026 profit was −$19.0 M, −2,949.1% on a year earlier. For the full year, FY25 profit was $5.9 M (−78.7% on the year before). Why profit moved: revenue changed +42.9% on a year earlier and the margin moved −14.7 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −880.3% and revenue +30.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does MannKind make, and is it growing? MannKind Corporation reported $109 M of revenue in the Jun 2026 quarter, +42.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 46.7% a year on average. The last full year, FY25, came in at $349 M. The last four reported quarters add to $394 M. FY25 revenue was $349 M, +22.2% on the year before. Recent pace: the last four quarters grew +30.3% on average, against 46.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +30.5%, against +25.9% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does MannKind keep? MannKind Corporation's operating margin was −0.8% in the Jun 2026 quarter, 14.7 percentage points lower than the same quarter a year ago. Across 5 years it has been between −70.4% and 24.1%. The latest quarter is within that range. Why the margin moved: operating margin changed −14.7 percentage points on the year while gross margin changed −0.1 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is MannKind's profit turning into cash? Over the last 2 years, 182% of MannKind Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $18.3 M of operating cash against $5.9 M of profit. After $4.6 M of spending on assets, $13.7 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does MannKind's cash go? MannKind Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $56.7 M on assets over the last 3 years. Averaged over those years that is 5.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $56.7 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is MannKind's P/E ratio, and how does it compare with its own history? MannKind Corporation's P/E is 217.2×, near the high end of its own history: higher than 75% of past readings. Its usual P/E (the middle reading) is 140.8×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −80.0% while the price moved −33.2%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the MannKind business getting better or worse? MannKind Corporation's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does MannKind earn on its capital? MannKind Corporation earned a ROE of −12% in FY25. That is up from a low of −35% in FY24. Its return on capital used (ROIC) is 12.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 1.7% net margin and 0.44× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 1.7% net margin × 0.44× asset turnover × −15.53× leverage (assets divided by equity) ≈ −11.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −2.3% − 10.0% = −12.3 percentage points. The 10.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −2.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 10.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does MannKind have too much debt? MannKind Corporation's net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from −1.83 in FY21 to −9.23 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the MannKind shareholding pattern? 8.6% of MannKind Corporation's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is MannKind from balance-sheet trouble? For MannKind Corporation, the Z-score is −4.42. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −4.42 is inside the danger zone, so the balance sheet is a real risk. ## How does MannKind rank in its industry? There is no score against its industry: MannKind Corporation is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is MannKind compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to MannKind in size? MannKind is the 103rd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Taysha Gene Therapies, Inc., UroGen Pharma and Nektar Therapeutics. Just below it: Silence Therapeutics plc, Inhibrx Biosciences, Inc. and Verastem, Inc. ### Biotechnology companies close in size

1. [Taysha Gene Therapies, Inc.](https://www.sectoralpha.in/us/stocks/tsha) $1.3 billion
2. [UroGen Pharma Ltd.](https://www.sectoralpha.in/us/stocks/urgn) $1.3 billion
3. [Nektar Therapeutics](https://www.sectoralpha.in/us/stocks/nktr) $1.2 billion
4. MannKind Corporation $1.2 billion
5. [Silence Therapeutics plc](https://www.sectoralpha.in/us/stocks/sln) $1.2 billion
6. [Inhibrx Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/inbx) $1.2 billion
7. [Verastem, Inc.](https://www.sectoralpha.in/us/stocks/vstm) $1.1 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Preferred Bank](https://www.sectoralpha.in/us/stocks/pfbc) $1.3 billion · Banks - Regional
2. [Ichor Holdings, Ltd.](https://www.sectoralpha.in/us/stocks/ichr) $1.3 billion · Semiconductor Equipment & Materials
3. MannKind Corporation $1.3 billion
4. [Lumexa Imaging Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lmri) $1.3 billion · Medical Devices
5. [Leggett & Platt, Incorporated](https://www.sectoralpha.in/us/stocks/leg) $1.3 billion · Furnishings, Fixtures & Appliances

## What else do people ask about MannKind? ### What were MannKind's latest quarterly results? MannKind Corporation reported revenue of $109 M and a net loss of $19.0 M for the Jun 2026 quarter. Revenue rose 42.9% and profit fell 2,949.1% compared with a year earlier. Earnings per share were −$0.06. The operating margin was −0.8%, 14.7 percentage points lower than a year earlier (as of 5 November 2026). ### What is MannKind's market cap? MannKind Corporation's market capitalisation is $1.2 B at a stock price of $3.76. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is MannKind performing? MannKind Corporation's latest readings are below. In its latest quarter, revenue rose 42.9% and profit fell 2,949.1% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 9 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will MannKind's stock price go up? This page does not forecast MannKind Corporation's stock price. What it shows instead: the stock price is $3.76. Its P/E of 217.2× is higher than 75% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is MannKind in its business cycle? MannKind Corporation's FY25 operating margin was 13.3%, against a 5-year range of −70.4% to 24.1%: the middle of its own range, neither a peak nor a low. The latest quarter was −0.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the MannKind story? The main question: the share price moved −33.2% in a year while yearly earnings per share moved −80.0%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is MannKind a stock worth studying right now? What the numbers show: MannKind Corporation's balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.